|
|
|
|
|
|
|
|
|
|
|
A conversation between Diana Colleluori and Life Science Connect's Jon O'Connell
|
Regulators expect cell therapy manufacturers to prove they control for visible particles, but guidance remains notably quiet on the matter. Companies must get creative or risk clinical holds.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Viral And Large-Scale Delivery Of Gene Editing Tools
|
|
Poster | By Hannah Goldfarb Wittkopf, Frank Morrissey-Wettey, Nadessa Poeppel, et al., Lonza
|
Advanced electroporation platforms enable reliable, large-scale delivery of complex gene editing tools like CRISPR/Cas9 to improve efficiency in primary T-cell manufacturing.
|
|
|
|
|
|
|
|
Automating Manufacturing Of Tumor-Reactive T Cells
|
|
Poster | Miltenyi Biotec
|
Uncover how CD137-based enrichment improves glioblastoma TIL manufacturing by expanding reactive T cell populations, preserving unique clonotypes, and strengthening autologous tumor cell killing.
|
|
|
|
|
|
|
|
|
|
The Practical Guide To Ergonomic Liquid Handling
|
|
E-Book | INTEGRA Biosciences
|
Even limited daily pipetting can increase the risk of repetitive strain injuries. Learn ways to improve posture, equipment selection, and workflow design while supporting long-term productivity.
|
|
|
|
|
|
|
|
|
|
Webinar: Rethinking Starting Material: Whole Blood for Autologous T-Cell Manufacture
|
Could whole blood offer a practical alternative to leukapheresis for selected autologous T-cell therapy workflows? This webinar explores fit-for-purpose starting-material selection, cell requirements, recovery, processing logistics, and key variables such as hold time and anticoagulant choice. Learn how closed, automated cell-isolation approaches may help simplify processing, reduce patient burden, and support efficient, reproducible manufacturing across evolving cell therapy workflows. Click here to learn more.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|